Neutralization of UK-variant VUI-202012/01 with COVAXIN vaccinated human serum
Preprint
- 26 January 2021
- preprint
- Published by Cold Spring Harbor Laboratory
Abstract
We performed the plaque reduction neutralization test (PRNT50) using sera collected from the recipients of BBV152/COVAXIN™ against hCoV-19/India/20203522 (UK-variant) and hCoV27 19/India/2020Q111 (heterologous strain). A comparable neutralization activity of the vaccinated individuals sera showed against UK-variant and the heterologous strain with similar efficiency, dispel the uncertainty of possible neutralization escape.Keywords
This publication has 6 references indexed in Scilit:
- New variant of SARS-CoV-2 in UK causes surge of COVID-19The Lancet. Respiratory Medicine, 2021
- SARS-CoV-2 escapein vitrofrom a highly neutralizing COVID-19 convalescent plasmaPublished by Cold Spring Harbor Laboratory ,2020
- Safety and immunogenicity clinical trial of an inactivated SARS-CoV-2 vaccine, BBV152 (a phase 2, double-blind, randomised controlled trial) and the persistence of immune responses from a phase 1 follow-up reportPublished by Cold Spring Harbor Laboratory ,2020
- Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: a phase 1, double-blind, randomised control trialPublished by Cold Spring Harbor Laboratory ,2020
- Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 BindingCell, 2020
- Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patientsIndian Journal of Medical Research, 2020